AstraZeneca oncology R&D chief Susan Galbraith: 'You're going to need orthogonal combinations'

John Carroll

Editor & Founder

Earlier in the week we broadcast our 4th annual European Biopharma Summit with a great lineup of top execs. One of the one-on-one conversations I set up was with Susan Galbraith, the oncology research chief at AstraZeneca. In a wide-ranging discussion, Galbraith reviewed the cancer drug pipeline and key trends influencing development work at the pharma giant. You can watch the video, above, or stick with the script below. — JC

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

TRENDING NOW

AstraZeneca oncology R&D chief Susan Galbraith: 'You're going to need orthogonal combinations'

John Carroll

Editor & Founder

To read Endpoints News become a free subscriber

FDA sets December approval decision for first CRISPR therapy, with 94% of patients free of sickle cell crises

Who pays the most (and least) in biopharma? We crunched median salary data from 175 companies

AstraZeneca enlists UK Treg biotech for type 1 diabetes, inflammatory bowel disease deal featuring $85M upfront

AstraZeneca fleshes out pivotal data on $930M rare blood disorder drug it wants to pair with Soliris, Ultomiris

Editas gives first look at CRISPR data in sickle cell, beta thalassemia six months after layoffs, refocus

The new rules of cancer care: Responding to increasing CMS influence on the oncology landscape

As­traZeneca on­col­o­gy R&D chief Su­san Gal­braith: 'Y­ou're go­ing to need or­thog­o­nal com­bi­na­tion­s'

John Carroll

Editor & Founder

To read Endpoints News become a free subscriber

FDA sets De­cem­ber ap­proval de­ci­sion for first CRISPR ther­a­py, with 94% of pa­tients free of sick­le cell crises

Who pays the most (and least) in bio­phar­ma? We crunched me­di­an salary da­ta from 175 com­pa­nies

As­traZeneca en­lists UK Treg biotech for type 1 di­a­betes, in­flam­ma­to­ry bow­el dis­ease deal fea­tur­ing $85M up­front

As­traZeneca flesh­es out piv­otal da­ta on $930M rare blood dis­or­der drug it wants to pair with Soliris, Ul­tomiris

Ed­i­tas gives first look at CRISPR da­ta in sick­le cell, be­ta tha­lassemia six months af­ter lay­offs, re­fo­cus

The new rules of can­cer care: Re­spond­ing to in­creas­ing CMS in­flu­ence on the on­col­o­gy land­scape

AstraZeneca oncology R&D chief Susan Galbraith: 'You're going to need orthogonal combinations'

FDA sets December approval decision for first CRISPR therapy, with 94% of patients free of sickle cell crises

Who pays the most (and least) in biopharma? We crunched median salary data from 175 companies

AstraZeneca enlists UK Treg biotech for type 1 diabetes, inflammatory bowel disease deal featuring $85M upfront

AstraZeneca fleshes out pivotal data on $930M rare blood disorder drug it wants to pair with Soliris, Ultomiris

Editas gives first look at CRISPR data in sickle cell, beta thalassemia six months after layoffs, refocus

The new rules of cancer care: Responding to increasing CMS influence on the oncology landscape